New combo therapy aims to shrink hard-to-treat liver tumors

NCT ID NCT06859684

Recruiting now Disease control Sponsor: West China Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new first-line treatment for people with advanced intrahepatic cholangiocarcinoma, a type of bile duct cancer that cannot be removed by surgery. The treatment combines chemotherapy directly into the liver artery (HAIC) with two drugs: durvalumab (an immunotherapy) and lenvatinib (a targeted therapy). The goal is to see if this triple approach shrinks tumors better than current standard treatments. About 25 participants will be enrolled.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DURVALUMAB are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cholangiocarcinoma Cirrhosis, Familial, with Pulmonary Hypertension intrahepatic cholangiocarcinoma nosocomial infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DURVALUMAB HAIC INTRAHEPATIC CHOLANGIOCARCINOMA (ICC)

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

West China Hospital, Sichuan University
RECRUITING

Chengdu, Sichuan, China

Contact Phone: •••-•••-•••• Email: •••••@•••••